GLP‑1s Aren’t The Solution
9:40–10:15 · 35s
Ashley Koff argues GLP‑1 agonists are not standalone fixes—even in dysfunction—calling them enablers for a personalized plan, not the solution.
9:40–10:15 · 35s
Ashley Koff argues GLP‑1 agonists are not standalone fixes—even in dysfunction—calling them enablers for a personalized plan, not the solution.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.